Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Allergic rhinitis is an inflammatory condition of the nasal passages induced after allergen exposure in sensitized individuals. Approximately 20-25% of Canadians suffer from allergic rhinitis, with cat allergy affecting up to 15% of people with allergic rhinitis and/or asthma. Although existing immunotherapies have some effectiveness, these have safety problems and require long-term treatment. A novel immunotherapy, Cat-Synthetic Peptide Immuno-Regulatory Epitopes (Cat-SPIRE), composed of seven synthetic molecules related to cat allergen, acts on allergen-specific immune cells to induce subsequent clinical tolerance to cat allergen with reduced side effects and a shorter treatment time. Its specific mechanism is not yet fully understood. Young Woong Kim will participate in a study to discover the mechanism using blood samples and clinical data obtained from research participants who have undertaken Cat-SPIRE clinical trials at Adiga Life Sciences, Inc. The investigation of the effects of Cat-SPIRE will allow us to find significant gene expression signatures for diagnosis and effectiveness of the treatments.
Young Woong Kim
Adiga Life Science Inc.
University of British Columbia
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.